Abstract
Purpose
Metformin has plausible direct and indirect anti-cancer properties against pancreatic adenocarcinoma cells. However, metformin may only be efficacious in patients with inoperable pancreatic ductal adenocarcinoma (PDAC) without liver metastases. Absorption may be decreased by gastrointestinal symptoms and proton pump inhibitors (PPIs). We aimed to justify and inform a future phase III trial of metformin versus placebo on survival in inoperable PDAC by documenting prevalence of patients meeting eligibility criteria, gastrointestinal symptoms and PPI use.
Methods
Patient notes with PDAC were reviewed at a large teaching hospital over 2 years. Study variables were obtained from multiple sources of information.
Results
141 participants were identified (51.8% female), of which 37.6% were not prescribed metformin at diagnosis and had no radiological hepatic metastases. Characteristics were similar between non-metformin and metformin users. In eligible patients, 65.2% reported nausea and vomiting and 46.2% were prescribed PPIs.
Conclusion
Approximately, a third of all patients with inoperable PDAC are eligible for a future trial of metformin, allowing an estimate of the number of hospitals required for recruitment. Nausea and vomiting are common and should be managed effectively to prevent trial dropouts. PPI use is frequent and their influence on metformin’s pharmacodynamic actions needs to be clarified.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Broadhurst PJ, Hart AR (2018) Metformin as an adjunctive therapy for pancreatic cancer: a review of the literature on its potential therapeutic use. Dig Dis Sci 63:2840–2852. https://doi.org/10.1007/s10620-018-5233-y
Chatterjee S, Khunti K, Davies MJ (2017) Type 2 diabetes. Lancet 389:2239–2251. https://doi.org/10.1016/s0140-6736(17)30058-2
Conroy T et al (2016) Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 57:10–22. https://doi.org/10.1016/j.ejca.2015.12.026
Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923
Dello SAWG, Stoot JHMB, van Stiphout RSA, Bloemen JG, Wigmore SJ, Dejong CHC, van Dam RM (2011) Prospective volumetric assessment of the liver on a personal computer by nonradiologists prior to partial hepatectomy. World J Surg 35:386–392. https://doi.org/10.1007/s00268-010-0877-6
Ding Y et al (2014) The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol 70:141–146. https://doi.org/10.1007/s00228-013-1604-7
Ferlay JSI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer. https://globocan.iarc.fr. Accessed 08 Sept 2017
Gonzalez-Guindalini FD, Botelho MP, Harmath CB, Sandrasegaran K, Miller FH, Salem R, Yaghmai V (2013) Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 33:1781–1800. https://doi.org/10.1148/rg.336135511
Graham GG et al (2011) Clinical pharmacokinetics of metformin. Clinical Pharmacokinet 50:81–98. https://doi.org/10.2165/11534750-000000000-00000
Kim A et al (2014) Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos 42:1174–1179. https://doi.org/10.1124/dmd.113.055616
Koepsell H (1998) Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol 60:243–266. https://doi.org/10.1146/annurev.physiol.60.1.243
Kordes S et al (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16:839–847. https://doi.org/10.1016/S1470-2045(15)00027-3
Mantatzis M, Kakolyris S, Amarantidis K, Karayiannakis A, Prassopoulos P (2009) Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate? Eur Radiol 19:1809–1816. https://doi.org/10.1007/s00330-009-1327-4
Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M (2011) Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE 6:e22163–e22163. https://doi.org/10.1371/journal.pone.0022163
Reni M et al (2016) (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res 22:1076–1085. https://doi.org/10.1158/1078-0432.ccr-15-1722
Rothe JH et al (2013) Size determination and response assessment of liver metastases with computed tomography—comparison of RECIST and volumetric algorithms. Eur J Radiol 82:1831–1839. https://doi.org/10.1016/j.ejrad.2012.05.018
Sasaoka T, Rose DW, Jhun BH, Saltiel AR, Draznin B, Olefsky JM (1994) Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 269:13689–13694
Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine. Clin Pharmacokinet 12:321–366. https://doi.org/10.2165/00003088-198712050-00002
Suzuki C et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329–344. https://doi.org/10.1148/rg.282075068
Wang L-W, Li Z-S, Zou D-W, Jin Z-D, Gao J, Xu G-M (2008) Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14:7192–7198. https://doi.org/10.3748/wjg.v14.i47.7192
Zhou G et al (2016) Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma. Curr Mol Med 16:83–90
Zhou K et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43:117–120. https://doi.org/10.1038/ng.735
Funding
Bursary award from Wolfson Foundation to P Broadhurst.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Broadhurst, P.J., Hart, A.R. An observational study to justify and plan a future phase III randomized controlled trial of metformin in improving overall survival in patients with inoperable pancreatic cancer without liver metastases. J Cancer Res Clin Oncol 146, 1369–1375 (2020). https://doi.org/10.1007/s00432-020-03177-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-020-03177-y